Volume 2.23 | Jun 17

Cord Blood News 2.23, June 17, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Cardiac Repair with Injectable Cell Sheet Fragments of Human Amniotic Fluid Stem Cells in an Immune-Suppressed Rat Model
In this study, human amniotic fluid stem cells were used as the cell source for the fabrication of cell sheet fragments, using a thermo-responsive methylcellulose hydrogel system. [Biomaterials]

MethoCult® Express Video  
Learn about the benefits of MethoCult® Express
for cord blood samples

by STEMCELL Technologies
 
 
WATCH THE VIDEO STEMCELL Technologies Inc
 


SCIENCE NEWS

Cord Blood Transplants a Viable Option in Leukemia
Researchers found that cord blood transplants are just as effective as bone marrow transplants for adult leukemia patients. [Press release from the Medical College of Wisconsin discussing online prepublication in Lancet Oncology]

Need to expand CD34+ cells?
StemSpan® serum-free expansion media are optimized for expanding hematopoietic stem and progenitor cells
REQUEST A SAMPLE STEMCELL Technologies Inc


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Efficient and Stable MGMT-Mediated Selection of Long-Term Repopulating Stem Cells in Nonhuman Primates
Researchers report efficient and stable methylguanine methyltransferase (MGMTP140K)-mediated multilineage selection in both macaque and baboon nonhuman primate models. [J Clin Invest]

Effect of Graft Source on Unrelated Donor Hemopoietic Stem-Cell Transplantation in Adults with Acute Leukemia: A Retrospective Analysis
Data support the use of umbilical cord blood for adults with acute leukemia when there is no HLA-matched unrelated adult donor available, and when a transplant is needed urgently. [Lancet Oncol]

Long-Term Follow-Up and Factors Influencing Outcomes After Related HLA-Identical Cord Blood Transplantation for Patients with Malignancies: An Analysis on Behalf of Eurocord-EBMT
Researchers analyzed risk factors influencing outcomes after related HLA-identical cord blood transplantation for 147 patients with malignancies reported to Eurocord-European Group for Blood and Marrow Transplantation (EBMT). [Blood]

An Injectable Calcium Phosphate-Alginate Hydrogel-Umbilical Cord Mesenchymal Stem Cell Paste for Bone Tissue Engineering
The objective of this study was to develop an injectable and mechanically-strong stem cell construct for bone tissue engineering using calcium phosphate cement paste combined with hydrogel microbeads encapsulating human umbilical cord mesenchymal stem cells. [Biomaterials]

Long-Term Efficacy and Safety of Human Umbilical Cord Mesenchymal Stromal Cells in Rotenone-Induced Hemiparkinsonian Rats
Results of this long-term study suggest that human umbilical cord mesenchymal stromal cells transplantation, one of the most potential treatments for Parkinson’s disease, is an effective and safe approach. [Biol Blood Marrow Transplant]

Influence of Nucleated Cell Dose on Overall Survival of Unrelated Cord Blood Transplant for Patients with Severe Acquired Aplastic Anemia: A Study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation
Results highlight the fundamental role of cell dose on both engraftment and overall survival in patients with severe aplastic anemia undergoing unrelated cord blood transplantation. [Biol Blood Marrow Transplant]

Comparison of Cytogenetic Clonal Evolution Patterns Following Allogenic Hematopoietic Transplantation versus Conventional Treatment in Patients at Relapse of Acute Myeloid Leukemia
Researchers compared karyotypes in 160 patients at both diagnosis and relapse either after allogeneic hematopoietic stem cell transplantation (n=26) or standard chemotherapy (n=134) using chromosome banding analysis combined with fluorescence in situ hybridization. [Biol Blood Marrow Transplant]

Genetic Variations of IL23R(1143A>G) and BPI(A645G) but not NOD2 are Associated with Acute GVHD After Allogenic Transplantation

NOD2-single nucleotide polymorphisms (SNPs) did not predict acute graft vs. host disease (aGVHD) whereas IL23R(1142A>G)– and BPI(A645G)-SNPs appeared to be promising markers in this regard. [Biol Blood Marrow Transplant]

Induction of Pluripotency in Human Cord Blood Unrestricted Somatic Stem Cells
Cord blood induced pluripotent stem cells are highly similar to human embryonic stem cells morphologically, at their molecular signature as well as in their differentiation potential. [Exp Hematol]


INDUSTRY NEWS

Lonza Announces Worldwide, Exclusive Licensing and Supply Agreements with California Stem Cell Inc.
Lonza Inc. has entered worldwide, exclusive licensing and supply agreements with California Stem Cell Inc. This collaboration makes novel pluripotent stem cell products readily available to researchers worldwide. [Lonza, Inc. Press Release]

AssureImmune, Florida’s Premier Stem Cell Collection and Preservation Company, Merges with Banco De Cordón Umbilical, the Largest Cord Blood Bank in Latin America
AssureImmune LLC announced their merger with Banco de Cordón Umbilical. [AssureImmune LLC Press Release]

Connecticut Awards $9.8 Million in Stem Cell Research Grants
Connecticut state has awarded $9.8 million in grants to support nearly two dozen stem cell research projects by scientists at the University of Connecticut and at Yale. [State of Connecticut Press Release]

STEMCELL Technologies is Proud to Announce STEMcircles™, a Virus-Free Technology for Reprogramming Cells
STEMCELL Technologies, Inc. announced that they have signed a licensing agreement with Stanford University for a virus-free technique used for the generation of induced pluripotent stem cells. [STEMCELL Technologies, Inc. Press Release]

International Stem Cell Corporation’s Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office
International Stem Cell Corporation announced that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic stem cells. [International Stem Cell Corporation Press Release]

NIH Approves Advanced Cell Technology’s Stem Cell Line for Federal Funding
Advanced Cell Technology, Inc. announced that human embryonic stem cell line MA135 was unanimously approved for federal funding at the 100th Meeting of the Advisory Committee to the Director National Institutes of Health (NIH). [Advanced Cell Technology, Inc. Press Release]

Lorus Therapeutics Announces Presentation of Phase II Clinical Trial Data for LOR-2040 in Acute Myeloid Leukemia
Lorus Therapeutics Inc. announced the presentation of Phase II clinical trial data for LOR-2040 (formerly known as GTI-2040) in combination with high dose cytarabine in the treatment of Acute Myeloid Leukemia. [Lorus Therapeutics Inc. Press Release]

Cord Blood America Educating on Stem Cell Storage
Cord Blood America, Inc. announced that Natalie Curry, the Company’s official spokesperson and medically saved by the first umbilical cord blood collection in the world, will discuss a wide range of topics about cord blood banking in a live webinar. [Cord Blood America, Inc. Press Release]

Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
CORD:USE’s Team of experts would like to clarify their specific support of CORD:USE’s family banking program, and to make it clear that their support of family cord blood banking is not a universal endorsement of all family banking enterprises or of unproven therapeutic uses of autologous cord blood cells. [PR Newswire]

Companies Pledge to Make More Trial Data Public
An international organization of pharmaceutical companies has adopted new guidelines governing the publication of clinical trial results. The policy calls for the industry to publish the results of late-stage, ‘phase 3′ clinical trials in peer-reviewed journals, regardless of the trials’ outcome. [NatureNews]

POLICY NEWS

The Path to Personalized Medicine
The leaders of the National Institutes of Health and the Food and Drug Administration have a shared vision of personalized medicine and the scientific and regulatory structure needed to support its growth. Together, they have been focusing on the best ways to develop new therapies and optimize prescribing by steering patients to the right drug at the right dose at the right time. [Food and Drug Administration and the National Institutes of Health, United States]

Diseased Cells Fail to Win Approval
In the latest obstacle to expanding the number of embryonic stem-cell lines eligible for U.S. federal funding, a National Institutes of Health committee has unanimously rejected dozens of cell lines carrying mutations for specific diseases. [National Institutes of Health, United States]

New Videos Reveal How NIH Identifies the Most Promising Research Applications
The National Institutes of Health’s Center for Scientific Review released a new video to show new applicants and others how NIH assesses over 80,000 grant applications each year to help find those with the most merit. [National Institutes of Health, United States]

NIH Researchers Explore How Healthy, Young Adults View the Role Genetics Plays in Improving Health
Most healthy young adults place greater emphasis on health habits than on genetic risk factors when considering what causes common diseases, a research team from the National Human Genome Research Institute and the Henry Ford Health System in Detroit has found. [National Institutes of Health, United States]

Charter of the Vaccines and Related Biological Products Advisory Committee
The Vaccines and Related Biological Products Advisory Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which the Food and Drug Administration has regulatory responsibility. [Food and Drug Administration, United States]

Hospital Clinic de Barcelona Obtained the First Accreditation for Cell Therapy Research
The certification, awarded for the first time in Catalonia, allows the Hospital Clinic de Barcelona to produce drugs in gene therapy, cell therapy and tissue engineering. [Spanish Medicines Agency, Spain]

Enhancing Peer Review: Advance Notice on Post-Submission Application Materials for NIH Training and Related Applications (NOT-OD-10-104) [National Institutes of Health, United States]

PFINDR: Phenotype Finder IN Data Resources: A Tool to Support Cross-study Data Discovery Among NHLBI Genomic Studies (UH2/UH3) (RFA-HL-11-020) [National Institutes of Health, United States]

Final Report of The National Academies’ Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to the National Academies’ Guidelines for Human Embryonic Stem Cell Research [National Academy of Sciences, United States]

Roster of the Cellular, Tissue and Gene Therapies Advisory Committee [Center for Biologics Evaluation and Research, United States]

Vaccines and Related Biological Products Advisory Committee Meeting Transcript [Food and Drug Administration, United States]

EVENTS

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

International Society for Cellular Therapy – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

International Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

AABB (formerly known as the American Association of Blood Banks) Annual Meeting & Cellular Therapy and Transfusion Medicine Expo (CTTXPO) 2010
October 9-12, 2010
Baltimore, United States

Institute for Genomic Medicine Inaugural Symposium
October 11-12, 2010
San Diego, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

World Cord Blood Congress
November 4-7, 2010
Marseille, France

Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC)
November 12-13, 2010
Tianjin, China

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

Visit
our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


 

JOB OPPORTUNITIES

Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)


Business Development Manager Europe – Cell Therapy Products (Pall Corporation)


Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Sr. Product Support and Training Specialist (CardianBCT)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cord Blood News.

Visit
here to post your career opportunities.



Have we missed an important article or publication in Cord Blood News? Click here to submit!

 

Comments or Suggestions? Email [email protected] with your feedback.

 

Learn more about Cord Blood News: Archives  |  Events  |  Subscribe  |  Contact Us